Stock 6657 ENERGENESIS BIOMEDICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Energenesis Biomedical CO.,LTD.

Equities

6657

TW0006657000

Biotechnology & Medical Research

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
55.6 TWD +1.09% Intraday chart for Energenesis Biomedical CO.,LTD. +3.73% -7.95%
Apr. 08 Energenesis Biomedical CO.,LTD. announced a financing transaction CI
Feb. 29 Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,302 4,751 2,926 2,997 2,858 4,592
Enterprise Value (EV) 1 2,009 4,127 2,397 2,283 2,382 3,901
P/E ratio -20 x -28.4 x -22.5 x -22.6 x -10.7 x -16.7 x
Yield - - - - - -
Capitalization / Revenue 495 x 760 x 413 x 400 x 389 x 642 x
EV / Revenue 432 x 660 x 339 x 305 x 324 x 545 x
EV / EBITDA -21.6 x -30 x -20.3 x -21.6 x -9.39 x -15.9 x
EV / FCF -39.2 x -59.6 x -47.8 x -39.9 x -16.1 x -30 x
FCF Yield -2.55% -1.68% -2.09% -2.51% -6.23% -3.33%
Price to Book 5.12 x 6.04 x 4.35 x 3.52 x 4.74 x 5.71 x
Nbr of stocks (in thousands) 48,779 58,662 59,355 66,371 66,845 76,025
Reference price 2 47.19 80.99 49.30 45.15 42.75 60.40
Announcement Date 4/9/19 3/27/20 4/19/21 4/12/22 2/18/23 2/29/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 4.65 6.251 7.081 7.489 7.351 7.158
EBITDA 1 -93.07 -137.7 -118.1 -105.6 -253.8 -244.6
EBIT 1 -108.7 -153.2 -133.6 -122.1 -271.7 -261.8
Operating Margin -2,336.71% -2,451.42% -1,886.54% -1,630.26% -3,695.47% -3,657.96%
Earnings before Tax (EBT) 1 -104.7 -149.8 -129.5 -120.2 -265.7 -260.4
Net income 1 -104.7 -149.8 -129.5 -120.2 -265.7 -260.4
Net margin -2,251.76% -2,395.98% -1,828.54% -1,605.5% -3,613.98% -3,637.64%
EPS 2 -2.356 -2.851 -2.192 -2.002 -3.987 -3.616
Free Cash Flow 1 -51.2 -69.21 -50.11 -57.24 -148.4 -129.8
FCF margin -1,101.05% -1,107.23% -707.64% -764.26% -2,018.78% -1,813.73%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/9/19 3/27/20 4/19/21 4/12/22 2/18/23 2/29/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 293 624 529 714 475 691
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -51.2 -69.2 -50.1 -57.2 -148 -130
ROE (net income / shareholders' equity) -29.6% -24.2% -17.7% -15.8% -36.5% -37%
ROA (Net income/ Total Assets) -16.9% -14.6% -11% -9.59% -22.4% -22.4%
Assets 1 619.6 1,027 1,178 1,254 1,187 1,161
Book Value Per Share 2 9.220 13.40 11.30 12.80 9.010 10.60
Cash Flow per Share 2 0.7700 1.860 1.250 2.250 1.350 3.240
Capex 1 2.73 1.77 2.71 8.9 6.45 0.84
Capex / Sales 58.67% 28.3% 38.29% 118.79% 87.7% 11.79%
Announcement Date 4/9/19 3/27/20 4/19/21 4/12/22 2/18/23 2/29/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENERGENESIS BIOMEDICAL CO.,LTD. Stock Energenesis Biomedical CO.,LTD.
-7.95% 128M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.63% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+12.14% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.90% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.64% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.35% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.42% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.04% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6657 Stock
  4. Financials Energenesis Biomedical CO.,LTD.